KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Non-Current Liabilities (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Total Non-Current Liabilities readings, the most recent being $759.1 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 3.63% to $759.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $759.1 million, a 3.63% increase, with the full-year FY2025 number at $759.1 million, up 3.63% from a year prior.
  • Total Non-Current Liabilities hit $759.1 million in Q4 2025 for Esperion Therapeutics, down from $807.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $807.9 million in Q3 2025 to a low of $332.8 million in Q4 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $400.9 million (2023), compared with a mean of $497.9 million.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 617.54% in 2021 and later tumbled 41.73% in 2022.
  • Esperion Therapeutics' Total Non-Current Liabilities stood at $332.8 million in 2021, then grew by 6.03% to $352.9 million in 2022, then rose by 19.26% to $420.8 million in 2023, then surged by 74.07% to $732.5 million in 2024, then increased by 3.63% to $759.1 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $759.1 million (Q4 2025), $807.9 million (Q3 2025), and $773.2 million (Q2 2025) per Business Quant data.